Wave Posts $61.9M Q3 Loss, Cash Runway to 3Q 2028, GSK Picks siRNA Candidate
WVE is trading near its 52-week low of $3.04 (13% above the low).
Summary
Wave reported a Q3 2026 net loss of $61.9 million, wider than the $53.9 million loss a year ago, as R&D rose to $53.8 million and G&A to $25.4 million. Revenue was $13.2 million versus $7.6 million in the prior-year quarter. Cash, equivalents and marketable securities stood at $431.0 million at September 30, down from $490.6 million at the end of Q2, and management says that funds operations into the third quarter of 2028, excluding a $12 million GSK milestone due in Q4. The pipeline update is the real content: planning is underway for a two-year registrational trial of WVE-006 in AATD with a one-year interim analysis for potential accelerated approval, WVE-007 dosing continues in the Phase 2a monotherapy and tirzepatide combination trials with a post-incretin maintenance trial on track for Q4, and a CTA for WVE-008 is slated for Q4 2026. GSK selected a development candidate using Wave's SpiNA siRNA design, triggering the $12 million milestone, with three more collaboration programs advancing. Watch the Q4 2026 data readouts for WVE-007 (600 mg SAD cohort) and WVE-006 (600 mg monthly multidose cohort), plus the November 4 Research Day.
At the time of this announcement, WVE was trading at $3.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $633.1M. The 52-week trading range was $3.04 to $21.73. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.